Disciplined Growth Investors Inc. MN Reduces Holdings in Medidata Solutions Inc (MDSO)

Share on StockTwits

Disciplined Growth Investors Inc. MN trimmed its position in Medidata Solutions Inc (NASDAQ:MDSO) by 0.7% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 926,154 shares of the company’s stock after selling 6,100 shares during the period. Medidata Solutions comprises 1.4% of Disciplined Growth Investors Inc. MN’s portfolio, making the stock its 28th biggest holding. Disciplined Growth Investors Inc. MN owned about 1.55% of Medidata Solutions worth $74,611,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in MDSO. World Asset Management Inc purchased a new position in Medidata Solutions in the second quarter worth about $235,000. Zeke Capital Advisors LLC purchased a new position in Medidata Solutions in the second quarter worth about $239,000. First Republic Investment Management Inc. purchased a new position in Medidata Solutions in the second quarter worth about $242,000. Asset Management One Co. Ltd. boosted its position in Medidata Solutions by 102.7% in the first quarter. Asset Management One Co. Ltd. now owns 3,948 shares of the company’s stock worth $248,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Zions Bancorporation purchased a new position in Medidata Solutions in the second quarter worth about $274,000.

MDSO stock opened at $80.53 on Friday. Medidata Solutions Inc has a twelve month low of $59.60 and a twelve month high of $88.87. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.41 and a current ratio of 1.41. The stock has a market cap of $4.80 billion, a PE ratio of 82.94, a P/E/G ratio of 5.04 and a beta of 1.45.

Medidata Solutions (NASDAQ:MDSO) last posted its quarterly earnings results on Tuesday, July 24th. The company reported $0.43 EPS for the quarter, topping the Zacks’ consensus estimate of $0.39 by $0.04. Medidata Solutions had a return on equity of 11.37% and a net margin of 9.13%. The company had revenue of $155.90 million for the quarter, compared to analysts’ expectations of $155.86 million. During the same period in the previous year, the firm earned $0.31 EPS. The firm’s revenue was up 14.6% compared to the same quarter last year. equities analysts forecast that Medidata Solutions Inc will post 0.79 earnings per share for the current fiscal year.

In related news, Director Robert Taylor sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 31st. The stock was sold at an average price of $73.05, for a total value of $365,250.00. Following the transaction, the director now directly owns 44,036 shares of the company’s stock, valued at approximately $3,216,829.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Rouven Bergmann sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, July 19th. The stock was sold at an average price of $85.36, for a total value of $256,080.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,788 shares of company stock worth $2,574,487. 4.70% of the stock is owned by insiders.

Several research analysts have issued reports on MDSO shares. Deutsche Bank raised their target price on Medidata Solutions from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, June 13th. Needham & Company LLC raised their target price on Medidata Solutions from $80.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, June 13th. ValuEngine raised Medidata Solutions from a “hold” rating to a “buy” rating in a research report on Monday, July 2nd. BidaskClub cut Medidata Solutions from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 26th. Finally, Deutsche Bank lifted their price objective on Medidata Solutions from $78.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, May 31st. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $87.62.

About Medidata Solutions

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.

See Also: Fiduciary

Want to see what other hedge funds are holding MDSO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medidata Solutions Inc (NASDAQ:MDSO).

Institutional Ownership by Quarter for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply